# Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)

> **NCT00040131** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 316 (actual)

## Conditions studied

- Bile Duct Diseases
- Biliary Tract Diseases
- Gallbladder Diseases
- Pancreatitis
- Pancreatic Diseases

## Interventions

- **DRUG:** IL-10

## Key facts

- **NCT ID:** NCT00040131
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-01
- **Primary completion:** 2002-12
- **Final completion:** 2003-01
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040131, "Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00040131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*